Skip to content


  • Review
  • Open Access

Regulation of PTEN expression by noncoding RNAs

Journal of Experimental & Clinical Cancer Research201837:223

  • Received: 26 June 2018
  • Accepted: 1 September 2018
  • Published:


Phosphatase and tensin homologue (PTEN) triggers a battery of intracellular signaling pathways, especially PI3K/Akt, playing important roles in the pathogenesis of multiple diseases, such as cancer, neurodevelopmental disorders, cardiovascular dysfunction and so on. Therefore PTEN might be a biomarker for various diseases, and targeting the abnormal expression level of PTEN is anticipated to offer novel therapeutic avenues. Recently, noncoding RNAs (ncRNAs) have been reported to regulate protein expression, and it is definite that PTEN expression is controlled by ncRNAs epigenetically or posttranscriptionally as well. Herein, we provide a review on current understandings of the regulation of PTEN by ncRNAs, which could contribute to the development of novel approaches to the diseases with abnormal expression of PTEN.


  • PTEN
  • Noncoding RNA
  • miRNA
  • lncRNA
  • Methylation
  • ceRNA


Phosphatase and tensin homologue (PTEN), also named as MMAC1 (mutated in multiple advanced cancers), is located on chromosome 10q23.31 [1, 2]. PTEN encodes a 403-amino acid peptide, which is composed of a phosphatidylinositol-4,5-bisphosphate-binding domain (PBD) (residues 1–13), a catalytic phosphatase domain (PD) (residues 14–185), a C2 membrane binding domain (C2D)(residues 186–350), and a C-terminal tail (residues 351–403) [3, 4]. The PD includes a conserved catalytic motif HCKAGKGR, contributing to the dual lipid and protein phosphatase activity of PTEN [4, 5]. The C2 domain includes two tyrosine phosphorylation sites (Y240 and Y315). The PDZ-binding domain (post-synaptic density protein (PSD95), Drosophila discs large (Dlg) and the tight junction protein zonula occludens-1 (ZO-1)) associates with the phosphatase activity, membrane association and stability of PTEN. There are two PDZ-binding domains and six phosphorylation sites in the C-terminal tail, including threonine 366 (Thr366), serine 370 (Ser370), Ser380, Thr382, Thr383 and Ser385 [611] (Fig. 1).
Fig. 1
Fig. 1

The Structure of PTEN. PTEN encodes a 403-amino acid peptide, which is composed of a phosphatidylinositol-4, 5-bisphosphate-binding domain (PBD) (residues 1–13), a catalytic phosphatase domain (PD) (residues 14–185), a C2 membrane binding domain (C2D)(residues 186–350), and a C-terminal tail (residues 351–403). The PD includes a conserved catalytic motif HCKAGKGR. The C2 domain includes two tyrosine phosphorylation sites (Y240 and Y315). There are two PDZ-binding domains (PDZ-BD) and six phosphorylation sites in the C-terminal tail. PDZ, post-synaptic density protein (PSD95), Drosophila discs large (Dlg) and the tight junction protein zonula occludens-1 (ZO-1)

PTEN contributes to the control of several important cellular signaling pathways. PTEN dephosphorylates phosphatidylinositol (3,4,5)-triphosphate (PIP3), therefore represses the activation of phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathway, Akt/ glycogen synthase kinase3(GSK-3)/Snail signaling pathway, or Akt/GSK-3/Wnt/ signaling pathway. Furthermore, GSK-3 interacts with and phosphorylates PTEN, which contributes to the inactivation of PTEN. Focal adhesion kinase (FAK) is dephosphorylated by PTEN directly, leading to the inactivation of FAK/p130Cas pathway. PTEN also dephosphorylates Src homology 2-containing protein (Shc) directly, and inhibits the activation of Shc/Raf/ERK1/2 (extracellular signal-regulated kinase) signaling cascade. Through controlling these pathways, PTEN ultimately represses cell survival, proliferation, metastasis and so on [1218] (Fig. 2).
Fig. 2
Fig. 2

The schematic representation of the major signaling pathways in which PTEN is involved. CK2, casein kinase II; PDZK1, PDZ-containing 1; GSK3, Glycogen synthase kinase3; FAK, Focal adhesion kinase; Rac, Ras-related C3 botulinum toxin substrate; SHC, Src homology 2-containing protein; MEK, MAPKK(mitogen-activated protein kinase kinase); ERK1/2, Extracellular signal-related kinase 1/2; PIP3, Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3); Akt, Protein kinase B (PKB); MDM2, Mouse double minute 2 homolog; TSC2, Tuberous Sclerosis Complex 2; mTORC, Mammalian target of rapamycin complex; CSCs, Cancer stem cells

PTEN expression alteration is crucial to the pathogenesis of cancer and other diseases. Low level of PTEN caused by homozygous deletions, frameshift, nonsense mutations or hypermethylation of the gene or destability of the protein occurs frequently in various human cancers [1923] and PTEN depletion in mice leads to a substantial rise in tumorigenesis [24, 25]. PTEN mutations were reported as a cause of obesity and autism spectrum disorders [2628]. PTEN protein level was decreased in an OVA-induced-asthma mouse model, and the administration of PTEN expressing adenovirus remarkably reduced bronchial inflammation and airway hyperresponsiveness [29]. However, high level of PTEN either contributes to pathological processes. Elevated PTEN expression was observed in endothelium of atherosclerotic brachial arteries from hemodialysis patients. PTEN overexpression stimulated the thrombosis formation of arteriovenous graft by inducing endothelial dysfunction [30]. PTEN negatively regulates neuron survival, and PTEN downregulation showed neuroprotective effects in mouse models of neuron death and Parkinson’s disease [31, 32]. Inhibition of PTEN rescued synaptic function and cognition in cellular and animal models of Alzheimer’s disease, whereas PTEN transgenic mice displayed synaptic depression [33]. In brief, abnormal PTEN expression level is associated to multiple diseases. Understanding the regulation mechanisms of PTEN expression and maintaining the homeostasis of PTEN should be beneficial.

The expression and activity of PTEN is modulated by several upstream molecules. P53 binds PTEN promoter and induces its transcription [34]. PDZK1 (PDZ-containing 1) induces PTEN dephosphorylation through binding the PDZ-binding domain in the PTEN C-terminal domain, which promotes the anti-oncogenic function of PTEN. Protein kinase CK2 (formerly casein kinase II) interacts with and phosphorylates PTEN C-terminal tail, which contributes to maintain PTEN stability [35]. Src inhibits PTEN activity to promote the post-ischaemic contractile recovery in apelin-induced cardioprotection [36]. Recently, with the development of the study on noncoding RNAs (ncRNAs), the control of PTEN expression by ncRNAs attracted more attention. Herein, we focus on the regulation of PTEN expression by ncRNAs, which is supposed to provide a reference for the coming laboratory and clinical studies on PTEN regulation (Fig. 3).
Fig. 3
Fig. 3

The regulation of PTEN expression. PTEN expression is dynamically regulated by various events, including genomic mutation or deletion, transcriptional, epigenetic, posttranscriptional, and posttranslational modulation. Noncoding RNAs epigenetically or posttranscriptionally regulate PTEN expression

More than 98% DNAs that do not encode proteins are called ncRNAs [37, 38]. In general, ncRNAs are classified into two groups as small ncRNAs (≤ 200 nt) and long ncRNAs (lncRNAs) (> 200 nt). MicroRNAs (miRNAs) (~ 18 to 24 nt) are an important group of small ncRNAs, which epigenetically or posttranscriptionally control the expression of the target mRNAs by pairing to them, leading to the alteration of transcription, mRNA stability or translation [3942]. LncRNAs take up a great proportion in the “transcriptome”, which play vital gene regulatory roles in the chromatin modification, transcriptional regulation, posttranscriptional regulation and so on [43, 44]. Emerging evidence indicates that PTEN functions in a dosage-dependent manner during tumor development [24, 45]. NcRNAs are key regulators of PTEN dosage, including miRNAs and lncRNAs, which delicately modulate the PTEN expression (Tables 1 and 2).
Table 1

Regulation of PTEN expression by miRNAs


PTEN expression






directly targeting PTEN mRNA

Gastric cancer, HNSCC, CCRCC




directly targeting PTEN mRNA

Bladder cancer, Breast invasive carcinoma, HCAECs injury, Inflammatory responses, PD, Lung adenocarcinoma, Colon adenocarcinoma




directly targeting PTEN mRNA





directly targeting PTEN mRNA

Lung cancer, Ovarian cancer

[60, 61]

miR-221 /222


directly targeting PTEN mRNA

NSCLC,HCC, TRAIL-induced cell death




directly targeting PTEN mRNA

Breast cancer, Neuronal death, Ewing’s carcoma, Melanoma, Insulin resistance




directly targeting PTEN mRNA

Tumorigenesis, Immunology, Cardiac injury




directly targeting PTEN mRNA

Ischemia/Reperfusion -induced myocardial injury

[72, 73]

miR-155-5p/130b/616/19/92a/10a/106a/429/26a /486-5p


directly targeting PTEN mRNA

HCC, NSCLC, Breast cancer, Lung cancer, Colorectal Cancer, Chronic myeloid leukemia, Intestinal cancer, Acute T-cell lymphoblastic leukemia




inducing the hypomethylation of PTEN promoter by inhibiting DNMT1, DNMT3b and SET1A expression

Liver fibrosis

[87, 88]



inducing the hypomethylation of PTEN promoter by inhibiting DNMT3A expression

Lung cancer

[89, 90]



inducing the hypomethylation of PTEN promoter by inhibiting DNMT1 expression



Table 2

Regulation of PTEN expression by lncRNAs


PTEN expression







acting as ceRNAs

miR-21, miR-17, miR-214, miR-19, miR-20, miR-93, miR-106b, miR-26

CCRCC, OSCC, HCC, Gastric cancer

[54, 96101]



acting as ceRNAs


Cardiac hypertrophy




acting as ceRNAs






acting as ceRNAs

miR-17, miR-20a, miR-20b, miR-93, miR-106a

Chronic myeloid leukemia




acting as both ceRNAs and downregulators of miRNAs

miR-21, miR-181a

Osteosarcoma, Glioma, Cervical cancer




acting as both ceRNAs and downregulators of miRNAs

miR-1297, miR-19a, miR-21

Breast cancer, Glioma, CAD




acting as both ceRNAs and downregulators of miRNAs

miR-21, miR-103, miR-196a, miR-205, miR-32-5p

HER2-positive breast cancer, HCC, NSCLC, Cardiac fibrosis, Endometrial cancer, Cervical cancer, Pancreatic cancer




acting as both ceRNAs and downregulators of miRNAs

miR-181a, MiR-494

HCC, Spinal Cord Injury

[121, 122]



acting as both ceRNAs and downregulators of miRNAs




lnc-2 /lnc-6


acting as both ceRNAs and downregulators of miRNAs


Prostate cancer, Glioma

[126, 127]



acting as both ceRNAs and downregulators of miRNAs


Colon cancer, Gastric cancer

[130, 131]



acting as both ceRNAs and downregulators of miRNAs


Liver fibrosis




increasing the stability and miRNA sponge activity of PTENP1




enhancing PTEN methylation via miRNA sponging


Liver Fibrosis, LSCC

[134, 135]



enhancing PTEN methylation via the recruitment of DNMT3a and EZH2


MiRNAs modulate PTEN expression

Altering PTEN expression by directly targeting PTEN mRNA

MiR-21 is one of the first identified mammalian microRNAs. The human miR-21 gene is located at chromosome 17q23.2 within a coding gene TMEM49 (also called vacuole membrane protein), which is highly conserved [46]. Early lineage tracing studies demonstrated that miR-21 was upregulated in various diseases, including acute pancreatitis [47], Myelodysplastic syndromes [48], severe steroid-insensitive allergic airway disease [49], liver cancer [50] and lung cancer [51].

PTEN is one of the important targets negatively regulated by miR-21. The 3′UTR of human PTEN contains a putative region that is able to pair to the seed sequence of miR-21 (Fig. 4). The exosomal miR-21 transferred from macrophages downregulated the PTEN level in gastric cancer cells, which resulted in the suppression of cell apoptosis and activation of PI3K/AKT signaling pathway [52]. Inhibition of miR-21 reversed EMT by increasing PTEN protein level in head and neck squamous cell carcinoma (HNSCC), resulting in the suppression of cell proliferation and motility [53]. MiR-21 was able to directly target the 3′UTR of PTEN, increasing clear-cell renal cell carcinoma (CCRCC) cell migration, invasion both in vitro and in vivo [54].
Fig. 4
Fig. 4

A Predicted miR-21 binding site within the 3’UTR of PTEN mRNA. By Target Scan Human Release 7.0 (

Expression of miR-130 family members has been recently reported to be correlated inversely to PTEN expression in bladder cancer, breast invasive carcinoma, lung adenocarcinoma and colon adenocarcinoma [55, 56]. Overexpression of miR-130a increased cell proliferation and motility via repression of PTEN expression, associated with the upregulation of FAK and Akt phosphorylation [5557]. MiR-130a decreases the PTEN level to activate PI3K/Akt/eNOS (endothelial nitric oxide synthase) signaling pathway, promoting human coronary artery endothelial cells (HCAECs) injury and inflammatory responses [57]. Exogenous expression of miR-130a prevented midbrain dopaminergic (mDA) neuron degeneration in Parkinson’s disease (PD) by suppressing the synthesis of PTEN [58].

Controversially, miR-130 was also found to be downregulated and positively correlated to PTEN levels in non-small cell lung cancer (NSCLC) tissue samples. The upregulation of miR-130 significantly increased PTEN expression, inhibited NSCLC cell growth and enhanced cell apoptosis both in vitro and in vivo [59]. Even the same pairing sequence of miR-130 and PTEN 3’UTR were used, opposite results were obtained in dual luciferase reporter assays from two reports. The relative activity of the luciferase harboring PTEN 3’UTR was promoted in A549 cells but repressed in 293 T cells by miR-130 [56, 59]. Although the mechanisms remain obscure, a tissue-specific pattern is possible for the regulation of PTEN by miR-130. MiR-130 might regulate PTEN expression through different ways according to the cellular context. PTEN protein was found to be slightly increased after the pre-miR-451-transfection in lung cancer cells [60]. Both miR-451 and PTEN expression level was reported to be significantly reduced in ovarian cancer [61].

Over the past decade, mountains of results show that the interaction of PTEN with miRNAs related to different diseases. MiR-221 and miR-222 were reported to be upregulated in aggressive NSCLC and hepatocarcinoma (HCC) cells, and conferred resistance to TNF-related apoptosis-inducing ligand (TRAIL)-induced cell death by targeting PTEN [62]. MiR-301a mediates the tumorigenesis of breast cancer, Ewing’s carcoma and melanoma, prevents neuronal death, and contributes to insulin resistance via decreasing PTEN protein level [6367]. MiR-214 induces tumorigenesis, stimulates immunology, and protects cardiac injury through inhibiting PTEN expression [6871]. MiR-494 targets PTEN and activates Akt pathway, leading to protect against ischemia/reperfusion -induced myocardial injury [72, 73]. There are also many other miRNAs directly targeting PTEN, such as miR-155-5p [74], miR-130b [75], miR-616 [76], miR-19 [77], miR-92a [78], miR-10a [79], miR-106a [80], miR-429 [81], miR-26a [82, 83] and miR-486-5p [84]. Consistent with miR-21, these miRNAs directly bind to the 3′UTR of human PTEN, and inhibit PTEN expression.

Upregulating PTEN expression by targeting DNA methyltransferases (DNMTs)

DNA methyltransferases (DNMTs) are the enzymes for DNA methylation, transferring a methyl group to the cytosine residues of DNA. DNA methylation of a gene promoter typically represses the gene transcription. The promoter region of the PTEN gene consists of three methylation sites. Overexpression of DNMT1 led to PTEN downregulation due to the CpG island methylation in promoter, which promoted tumorigenesis of breast cancer, ovarian cancer and acute myeloid leukemia (AML) [85, 86]. MiRNAs targeting DNMTs increase the PTEN expression. MiR-29a was found to inhibit DNMT1, DNMT3b and SET domain containing 1A (SET1A) expression, resulting in elevated PTEN expression and decreased offibrogenic activities in hepatic stellate cells (HSCs) [87]. Curcumin treatment suppressed liver fibrosis by inducing miR-29b expression in HSCs, which led to the low expression of DNMT3b and PTEN hypomethylation [88] (Fig. 5). Bioinformatics and dual luciferase reporter assays demonstrated that DNMT3A is a target of miR-101 [89]. Introduction of miR-101 inhibitor increased the protein level of DNMT3A instead of the mRNA expression. Overexpression of miR-101 or silencing of DNMT3A induced the hypomethylation of PTEN promoter which was verified by a methylation specific PCR assay [90]. The expression of miR-185 was inhibited in cultured human HCC cells [91]. Introduction of miR-185 mimics significantly reduced DNMT1 expression, decreased PTEN promoter methylation and increased the protein level of PTEN. MiR-185 overexpression decreased the reporter activity of the luciferase with DNMT1 3’UTR, and forced expression of DNMT1 reversed the loss of PTEN promoter methylation mediated by miR-185.
Fig. 5
Fig. 5

MiR-29a upregulates PTEN expression by targeting DNMTs. MiR-29a could repress DNMTs at posttranscriptional level, resulting in a decrease of CpG island methylation of the PTEN promoter. DNMTs, DNA methyltransferases

LncRNAs modulate PTEN expression indirectly

LncRNAs have multiple important functions in cellular and developmental processes. LncRNAs may carry out both gene inhibition and activation through diverse mechanisms [43, 44]. The studies on the lncRNAs associated with PTEN suggest that lncRNAs modulate PTEN expression by altering either the related miRNAs or promoter methylation.

Acting as competing endogenous RNAs (ceRNAs)

LncRNAs can act as competing endogenous RNAs (ceRNAs) to indirectly regulate mRNAs through the shared miRNAs. LncRNAs compete the seed sites of miRNAs with their target mRNAs, leading to block the effects of miRNAs on the mRNA targets [9295].

PTENP1, located on chromosome 9p21, is a highly conserved pseudogene of PTEN. Gan Yu et al. reported the low expression of PTENP1 due to methylation in CCRCC tissues and cell lines. Both PTEN and PTENP1 expression is inversely correlated with miR-21 expression. In miR-21 overexpressing cells, PTENP1 introduction suppressed cell proliferation and metastasis, and increased the cell sensitivity to cisplatin and gemcitabine, restoring the phenotypes induced by PTEN in vitro and in vivo [54]. Activation of PTENP1 partially inhibited the suppression of PTEN by miR-21 in oral squamous cell carcinoma (OSCC) tumor xenografts [96]. Evidences have revealed that PTENP1 expression level is positively related to PTEN transcript, and PTENP1 protects PTEN mRNA through serving as a decoy for miRNAs, such as miR-21, miR-17, miR-214, miR-19, miR-20, miR-93, miR-106b and miR-26 families [5, 54, 97101] (Fig. 6).
Fig. 6
Fig. 6

PTENP1 works as a ceRNA to promote PTEN expression. PTENP1 recruits miRNAs such as miR-181a and miR-21, therefore impairs the miRNAs binding PTEN

Homeobox (HOX) transcript antisense RNA (HOTAIR) is encoded within the HoxC gene cluster on chromosome 12, which silences the expression of HoxD genes and numerous tumor and metastasis suppressors [102, 103] by interacting with chromatin-remodeling enzymes [104]. On the contrary, HOTAIR regulates PTEN expression as a ceRNA. HOTAIR expression decreased notably in sustained cardiac hypertrophy mouse models, in which miR-19 expression was increased and inversely correlated with HOTAIR expression. HOTAIR has a binding site for miR-19 seed sequence, and HOTAIR overexpression restored the inhibition of luciferase activity with PTEN 3’UTR mediated by miR-19 [105].

Linc-USP16 acted as a ceRNA for miR-21 and miR-590-5p, promoting PTEN expression to repress the growth and stimulate apoptosis in HCC in vivo and in vitro [106]. LncRNA-BGL3 worked as a ceRNA for miR-17, miR-93, miR-20a, miR-20b, miR-106a and miR-106b, rescuing the repression of PTEN expression to inhibit Bcr-Abl-induced cellular transformation [80].

Acting as both ceRNAs and downregulators of miRNAs

LncRNAs can also decrease the expression level of miRNA as well as being sponges, leading to suppress the effects of miRNAs on their mRNA targets.

Cancer susceptibility candidate 2 (CASC2), mapped to chromosome 10q26, encodes a lncRNA which acts as a ceRNA of miR-21 or miR-181a and exerts biological effects by increasing the expression of PTEN [107, 108]. The expression of CASC2 is significantly downregulated in glioma, osteosarcoma or cervical cancer tissues and cell lines, and CASC2 expression level is negatively correlated to miR-181a level in glioma tissues. CASC2 overexpression significantly repressed cell proliferation, and amplified temozolomide- or cisplatin-induced repression of cell proliferation in vitro, which was associated with the downregulation of miR-181a and miR-21. CASC2 overexpression upregulated PTEN level, which was partially restored by miR-181a and miR-21 mimics. In addition, CASC2 was found to interact directly with miR-181a and miR-21 in dual-luciferase reporter assays [108, 109].

Maternally expressed gene 3 (MEG3), encoding a lncRNA, is located at the chromosome 14q32. In testicular germ cell tumor (TGCT) tissues, lncRNA MEG3 level is significantly decreased, while PTEN protein but not mRNA levels are notably downregulated [110]. Bioinformatics analyses showed that miR-1297 bound not only 3’UTR of PTEN mRNA but also MEG3 [111]. MEG3 overexpression disturbed the binding of miR-1297 to 3’UTR of PTEN mRNA and remitted the reduction of PTEN induced by miR-1297. MEG3 downregulation and miR-19a upregulation were reported in malignant glioma tissues and cell lines, and luciferase results verified the complementary binding between miR-19a and MEG3. MiR-19a overexpression repressed the expression of PTEN and promoted glioma cell proliferation, migration, and invasion [112]. Moreover, in the coronary artery disease (CAD) tissues, MEG3 level declines, and miR-21 expression has negative correlation with MEG3 expression. Overexpression of MEG3 suppressed miR-21 expression, promoted the expression of PTEN, and suppressed the proliferation of endothelial cells [113].

LncRNA growth arrest specific transcript 5 (lncRNA GAS5) is downregulated in NSCLC, breast cancer and HCC tissues, and lncRNA GAS5 knockdown repressed cell viability. lncRNA GAS5 competes with PTEN to bind miR-21, and depletion or overexpression of lncRNA GAS5 could increase or decrease miR-21 expression, resulting in the downregulation or upregulation of PTEN level in these tumor cells [114116]. A low expression of lncRNA GAS5 and an upregulation of miR-21 are reported in cardiac fibrosis. The downregulation of PTEN expression mediated by miR-21 mimics was reversed by overexpressing lncRNA GAS5 in cardiac fibroblast cells [117]. LncRNA GAS5 could also induce PTEN expression by inhibiting miR-103 [118], miR-196a and miR-205 [119], and miR-32-5p [120].

The lncRNA X inactivate-specific transcript (XIST) directly interacts with miR-181a, and they repress the expression of each other. XIST overexpression restored the PTEN downregulation induced by miR-181a mimics, and transfection with XIST siRNA significantly enhanced the proliferation and invasion of liver cancer cells together with a decreased PTEN level [121]. Neuronal apoptosis and lncRNA XIST expression level were found to be promoted in an spinal cord injury model. XIST acts as a sink for miR-494, leading to derepression of PTEN. MiR-494 expression was upregulated with XIST knockdown, whereas was downregulated with XIST overexpression. AntagomiR-494 treatment reversed the protective effects of XIST depletion on spinal cord injury through blocking the PTEN/PI3K/AKT signaling pathway [122].

The low expression of LncRNA neuroblastoma associated transcript 1 (NBAT1) in osteosarcoma tissues and cells was closely correlated to clinical stages, lymph node metastasis and poor prognosis [123]. NBAT1 binds miR-21, and suppresses miR-21 expression. NBAT1 overexpression downregulated osteosarcoma growth and metastasis via acting as a ceRNA against miR-21, which was associated with PTEN upregulation in vitro and in vivo.

The expression of lnc-2 and lnc-6 showed positive correlation with PTEN in prostate cancer cohorts [124, 125]. Knockdown of lnc-2 or lnc-6 led to a significant decrease in PTEN expression at both protein and mRNA levels and a significant increase in cell proliferation. On the contrary, depletion of PTEN reduced the expression of both lnc-2 and lnc-6,and the reduction of PTEN expression by overexpressing known PTEN-regulating miRNAs could be rescued by overexpressing lnc-2 sub-sequences [126]. PTEN and lnc-6 are downregulated while miR-26a is upregulated in human glioma. Lnc-6 introduction into glioma cells resulted in a decrease of miR-26a expression [127].

Microarray and real time PCR results showed that lncRNA fer-1-like family member 4 (FER1L4) was downregulated in gastric cancer, endometrial carcinoma and colon cancer tissues or cell lines [128]. Enforced expression of FER1L4 increased PTEN expression at both mRNA and protein levels, which might contribute to cell cycle arrest and apoptosis [129]. In colon cancer cell lines, FER1L4 expression is inversely correlated with miR-106a-5p expression [130]. Luciferase assay results suggested direct interactions between miR-106a-5p and FER1L4 or PTEN. Knockdown of FER1L4 increased miR-106a-5p expression level and decreased the levels of PTEN mRNA and protein [130, 131].

Fujun Yu et al. reported a novel lincRNA-p21-miR-181b-PTEN signaling cascade in liver fibrosis [132]. LincRNA-p21 overexpression significantly suppressed the isolated rat HSC activation and the expression of extracellular matrix (ECM) proteins, which was reversed by depletion of PTEN. MiR-181b binds lincRNA-p21, and miR-181b level was reduced by exogenous lincRNA-p21, while the effects of lincRNA-p21 on PTEN expression and HSC activation were inhibited by miR-181b mimics.

Increasing the stability of lncRNAs

PTENP1, also encodes antisense RNAs (asRNAs), which has two isoforms, α and β. PTENP1 asRNA β interacts with PTENP1 through an RNA:RNA pairing interaction, and the stability of PTENP1 was decreased when the interaction was interfering using U6 encoded ssRNAs or PTENP1 asRNA β was knocked down. Thus PTENP1 asRNA β upregualtes PTEN level via increasing the stability and miRNA sponge activity of PTENP1 [133].

Prompting the methylation of PTEN promoter

HOTAIR expression is upregulated in HSCs during liver fibrosis. HOTAIR knockdown suppressed HSC proliferation and activation in vitro and in vivo, increasing PTEN level, with the loss of DNA methylation mediated by miR-29b [134]. HOTAIR levels were significantly higher in human laryngeal squamous cell cancer (LSCC), and bisulfite sequencing of the PTEN promoter addressed that PTEN CpG islands were unmethylated in HOTAIR siRNA-transduced cells and PTEN methylation was significantly reduced [135]. Collectively, HOTAIR might contribute to PTEN promoter methylation via sponging miR-29b.

The expression of PTEN and PTENP1 asRNA α is negatively correlated in cell lines, and the α depletion resulted in the increase of PTEN transcript. PTENP1 asRNA α binds the PTEN promoter, and epigenetically downregulates PTEN transcription by the recruitment of DNMT3a and Enhancer of zeste homolog 2 (EZH2) to enhance the methylation of PTEN promoter. PTENP1 asRNA α knockdown induces cell cycle arrest and sensitizes cells to doxorubicin, suggesting the biological function for the PTENP1 asRNAs [133, 136].

Conclusions and future directions

Due to the essential physiological function of PTEN, the ncRNAs controlling PTEN expression play crucial roles in various biological activation, such as autophagy and cell stemness. PTEN induces autophagy through repressing PI3K/Akt pathway, while miR-21 elevation was found in human degenerative nucleus pulposus tissues, which inhibits autophagy and induces ECM degradation via repressing PTEN expression [137]; Human aortic smooth muscle cell-derived exosomal miR-221/222 suppressed the autophagy in human umbilical vein endothelial cells by regulating PTEN/Akt signaling pathway in a co-culture system [138]; MiR-21-5p significantly increases cell stemness of keloid keratinocytes, mediated by PTEN repression and AKT activation, which may account for the invasion and recurrence of keloids [139]. MiR-10b promotes cellular self-renewal and expression of stemness markers in breast cancer stem cells through negative regulation of PTEN and sustained activation of AKT [140].

Actually, therapeutic strategies for multiple diseases focus on PI3K/Akt pathway inhibitors. However, the therapeutic benefit is modest due to the network complexities [141, 142]. PTEN modulation has been considered as a possible approach to tumor and other diseases. NcRNAs including lncRNAs and miRNAs act alone or interact with each other to regulate PTEN expression. Elucidation of the details that ncRNAs modulate PTEN expression may provide novel insights into the regulation network of PTEN, which could suggest possible strategies to target PI3K/Akt pathway.

Primary therapeutic attempts targeting ncRNAs to alter the PTEN expression have shown effects. Sophocarpine, a tetracyclic quinolizidine alkaloid derived from Sophora alopecuroides L, has shown inhibitory effects on HNSCC progression via the downregulation of miR-21 and the upregulation of PTEN in vivo and in vitro [53]. Ursolic acid exerted protective action on high glucose-induced cell podocyte injury via decreasing miR-21 expression, which resulted in an increase of PTEN level [143]. Combination of STAT3 inhibitor and DDP treatment led to a notable reduction of STAT3/miR-21 axis and an increase of PTEN level, repressing oral squamous cell carcinoma (OSCC) cell proliferation, migration and invasion [144].

As-miR-21 treatment presented an obvious inhibition on established glioma tumor growth and an increase in PTEN expresson. Coincidently, in a prostate xenograft model, injection of as-miR-4534 led to a significant reduction in tumor volume, which increased the expression level of PTEN [145]. In a spontaneously developed lung tumors mouse model, treatment with the miR-214 antisense oligonucleotides microvesicles displayed promotion of PTEN levels and reduction of growth of spontaneous lung tumors [68]. Furthermore, administration of LNA-antimiR-19a increased the sensitivity of multidrug resistant MCF-7 cells to Taxol in vivo, with an upregulation of PTEN verified [146]. The growth of human LSCC xenograft was remarkably inhibited by HOTAIR shRNA lentivirus treatment [135], and injection of the PTENP1-expressing baculovirus effectively mitigated the HCC xenograft tumor growth, which was associated with the increase of PTEN [97].

In term of the importance of PTEN expression level in physiological situation and pathogenesis of various diseases, modulating PTEN level could be considered as potential approaches for multiple diseases, while clarifying the regulation network of PTEN including ncRNAs is predicted to be able to provide novel strategies.



Myeloid leukemia


C2 membrane binding domain


Coronary artery disease


Cancer susceptibility candidate 2


Clear-cell renal cell carcinoma


Competing endogenous RNAs


Formerly casein kinase II


Cancer stem cells


DNA methyltransferases


Extracellular matrix


Mesenchymal transition


Endothelial nitric oxide synthase (eNOS)


Extracellular signal-regulated kinase


Focal adhesion kinase


lncRNA fer-1-like family member 4


Glycogen synthase kinase3


Human coronary artery endothelial cells


Head and neck squamous cell carcinoma


Homeobox (HOX) transcript antisense RNA


Hepatic stellate cell

lncRNA GAS5: 

lncRNA growth arrest specific transcript 5


Long ncRNAs


Laryngeal squamous cell cancer


Midbrain dopaminergic


Maternally expressed gene 3


Small ncRNAs


Mutated in multiple advanced cancers


Mammalian target of rapamycin complex


LncRNA neuroblastoma associated transcript 1


Noncoding RNAs


Non-small cell lung cancer


Oral squamous cell carcinoma


Phosphatidylinositol-4,5-bisphosphate-binding domain


A catalytic domain phosphatase domain


Parkinson’s disease


Post-synaptic density protein (PSD95), Drosophila discs large (Dlg) and the tight junction protein zonula occludens-1 (ZO-1)


PDZ-containing 1


Phosphatidylinositol 3-kinase


Phosphatidylinositol (3,4,5)-triphosphate


Phosphatase and tensin homologue


Pseudogene of PTEN


SET domain containing 1A


Src homology 2-containing protein


Testicular germ cell tumor


TNF-related apoptosis-inducing ligand


Tuberous Sclerosis Complex 2


lncRNA X inactivate-specific transcript



This work was supported by Liaoning Provincial program for Top Discipline of Basic Medical Sciences. We thank all the members of Huang lab for kind support.


This work was supported by the Climbing Scholars Supporting Program of Liaoning; and National Natural Science Foundation of China (81772971).

Authors’ contributions

WL and LH designed and wrote the paper; WL, TZ, LG and LH collected and read the references, and made the figures. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Pathophysiology, College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning, 116044, People’s Republic of China


  1. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15(4):356–62.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Shinde SR, Maddika S. PTEN regulates glucose transporter recycling by impairing SNX27 Retromer assembly. Cell Rep. 2017;21(6):1655–66.PubMedView ArticlePubMed CentralGoogle Scholar
  3. Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecot T, et al. Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes Dev. 2015;29(16):1707–20.PubMedView ArticlePubMed CentralGoogle Scholar
  4. Kim DH, Suh J, Surh YJ, Na HK. Regulation of the tumor suppressor PTEN by natural anticancer compounds. Ann N Y Acad Sci. 2017;1401(1):136–49.PubMedView ArticlePubMed CentralGoogle Scholar
  5. Uversky VN, Dave V, Iakoucheva LM, Malaney P, Metallo SJ, Pathak RR, et al. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev. 2014;114(13):6844–79.PubMedView ArticlePubMed CentralGoogle Scholar
  6. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99(3):323–34.PubMedView ArticlePubMed CentralGoogle Scholar
  7. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403–14.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Shnitsar I, Bashkurov M, Masson GR, Ogunjimi AA, Mosessian S, Cabeza EA, et al. PTEN regulates cilia through Dishevelled. Nat Commun. 2015;6:8388.PubMedView ArticlePubMed CentralGoogle Scholar
  9. Adey NB, Huang L, Ormonde PA, Baumgard ML, Pero R, Byreddy DV, et al. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res. 2000;60(1):35–7.PubMedPubMed CentralGoogle Scholar
  10. Meiling-Wesse K, Epple UD, Krick R, Barth H, Appelles A, Voss C, et al. Trs85 (Gsg1), a component of the TRAPP complexes, is required for the organization of the preautophagosomal structure during selective autophagy via the Cvt pathway. J Biol Chem. 2005;280(39):33669–78.PubMedView ArticlePubMed CentralGoogle Scholar
  11. Valiente M, Andrés-Pons A, Gomar B, Torres J, Gil A, Tapparel C, et al. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J Biol Chem. 2005;280(32):28936–43.PubMedView ArticlePubMed CentralGoogle Scholar
  12. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, et al. Integrated molecular characterization of uterine Carcinosarcoma. Cancer Cell. 2017;31(3):411–23.PubMedView ArticlePubMed CentralGoogle Scholar
  13. Gemmill RM, Nasarre P, Nair-Menon J, Cappuzzo F, Landi L, D'Incecco A, et al. The neuropilin 2 isoform NRP2b uniquely supports TGF beta-mediated progression in lung cancer. Science Signaling. 2017;10(462):eaag0528.PubMedView ArticlePubMed CentralGoogle Scholar
  14. Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, et al. Resveratrol reverses doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2017;36(1):19.PubMedView ArticlePubMed CentralGoogle Scholar
  15. Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, et al. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget. 2017;8(32):53068–83.PubMedView ArticlePubMed CentralGoogle Scholar
  16. Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell. 2013;153(5):1050–63.PubMedView ArticlePubMed CentralGoogle Scholar
  17. McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 2017;8(8):14221–50.PubMedView ArticlePubMed CentralGoogle Scholar
  18. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, et al. Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell. 2015;27(1):109–22.PubMedView ArticlePubMed CentralGoogle Scholar
  19. Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, et al. Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clinical Cancer Res. 2017;23(21):6686–96.View ArticleGoogle Scholar
  20. Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of Phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors. JAMA Oncol. 2016;2(12):1565–73.PubMedView ArticlePubMed CentralGoogle Scholar
  21. Li J, Yan S, Liu Z, Zhou Y, Pan Y, Yuan W, et al. Multiregional sequencing reveals genomic alterations and clonal dynamics in primary malignant melanoma of the esophagus. Cancer Res. 2017;78:338–47.PubMedView ArticlePubMed CentralGoogle Scholar
  22. Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, et al. Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. Nat Commun. 2017;8(1):1450.PubMedView ArticlePubMed CentralGoogle Scholar
  23. Wan S, Meyer AS, Weiler SME, Rupp C, Toth M, Sticht C, et al. Cytoplasmic localization of the cell polarity factor Scribble supports liver tumor formation and tumor cell invasiveness. Hepatology (Baltimore, Md). 2017;67:1842–56.View ArticleGoogle Scholar
  24. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42(5):454–8.PubMedView ArticlePubMed CentralGoogle Scholar
  25. Shen-Li H, Koujak S, Szablocs M, Parsons R. Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice. Cancer Biol Ther. 2010;10(11):1194–200.PubMedView ArticlePubMed CentralGoogle Scholar
  26. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet. 2005;42(4):318–21.PubMedView ArticlePubMed CentralGoogle Scholar
  27. Pal A, Barber TM, Van de Bunt M, Rudge SA, Zhang Q, Lachlan KL, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012;367(11):1002–11.PubMedView ArticlePubMed CentralGoogle Scholar
  28. Garcia-Junco-Clemente P, Golshani P. PTEN: a master regulator of neuronal structure, function, and plasticity. Commun Integrative Biol. 2014;7(1):e28358.View ArticleGoogle Scholar
  29. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS, Lee KS, et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest. 2003;111(7):1083–92.PubMedView ArticlePubMed CentralGoogle Scholar
  30. Kuo HM, Lin CY, Lam HC, Lin PR, Chan HH, Tseng JC, et al. PTEN overexpression attenuates angiogenic processes of endothelial cells by blockade of endothelin-1/endothelin B receptor signaling. Atherosclerosis. 2012;221(2):341–9.PubMedView ArticlePubMed CentralGoogle Scholar
  31. Domanskyi A, Geissler C, Vinnikov IA, Alter H, Schober A, Vogt MA, et al. Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J. 2011;25(9):2898–910.PubMedView ArticlePubMed CentralGoogle Scholar
  32. Liu B, Li L, Zhang Q, Chang N, Wang D, Shan Y, et al. Preservation of GABAA receptor function by PTEN inhibition protects against neuronal death in ischemic stroke. Stroke. 2010;41(5):1018–26.PubMedView ArticlePubMed CentralGoogle Scholar
  33. Knafo S, Sanchez-Puelles C, Palomer E, Delgado I, Draffin JE, Mingo J, et al. PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. Nat Neurosci. 2016;19(3):443–53.PubMedView ArticlePubMed CentralGoogle Scholar
  34. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8(2):317–25.PubMedView ArticlePubMed CentralGoogle Scholar
  35. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276(2):993–8.PubMedView ArticlePubMed CentralGoogle Scholar
  36. Folino A, Accomasso L, Giachino C, Montarolo PG, Losano G, Pagliaro P, et al. Apelin-induced cardioprotection against ischaemia/reperfusion injury: roles of epidermal growth factor and Src. Acta Physiol. 2018;222:e13005.View ArticleGoogle Scholar
  37. Taft RJ, Pheasant M, Mattick JS. The relationship between non-protein-coding DNA and eukaryotic complexity. BioEssays. 2007;29(3):288–99.PubMedView ArticlePubMed CentralGoogle Scholar
  38. Esteller M, Pandolfi PP. The Epitranscriptome of noncoding RNAs in Cancer. Cancer Discovery. 2017;7(4):359–68.PubMedView ArticlePubMed CentralGoogle Scholar
  39. Telonis AG, Magee R, Loher P, Chervoneva I, Londin E, Rigoutsos I. Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. Nucleic Acids Res. 2017;45(6):2973–85.PubMedView ArticlePubMed CentralGoogle Scholar
  40. Ahadi A, Sablok G, Hutvagner G. miRTar2GO: a novel rule-based model learning method for cell line specific microRNA target prediction that integrates Ago2 CLIP-Seq and validated microRNA-target interaction data. Nucleic Acids Res. 2017;45(6):e42.PubMedView ArticlePubMed CentralGoogle Scholar
  41. Dooley J, Lagou V, Garcia-Perez JE, Himmelreich U, Liston A. miR-29a-deficiency does not modify the course of murine pancreatic acinar carcinoma. Oncotarget. 2017;8(16):26911–7.PubMedView ArticlePubMed CentralGoogle Scholar
  42. Engreitz JM, Sirokman K, McDonel P, Shishkin AA, Surka C, Russell P, et al. RNA-RNA interactions enable specific targeting of noncoding RNAs to nascent pre-mRNAs and chromatin sites. Cell. 2014;159(1):188–99.PubMedView ArticlePubMed CentralGoogle Scholar
  43. Runtsch MC, O'Neill LA. GOTcha: lncRNA-ACOD1 targets metabolism during viral infection. Cell Res. 2018;28:137–8.PubMedView ArticlePubMed CentralGoogle Scholar
  44. Michelini F, Pitchiaya S, Vitelli V, Sharma S, Gioia U, Pessina F, et al. Damage-induced lncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks. Nat Cell Biol. 2017;19(12):1400–11.PubMedView ArticlePubMed CentralGoogle Scholar
  45. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res. 2010;70(18):7114–24.PubMedView ArticlePubMed CentralGoogle Scholar
  46. Ge Y, Zhang L, Nikolova M, Reva B, Fuchs E. Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21( *) in SCC progression. Nat Cell Biol. 2016;18(1):111–21.PubMedView ArticlePubMed CentralGoogle Scholar
  47. Ma X, Conklin DJ, Li F, Dai Z, Hua X, Li Y, et al. The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun. 2015;6:7151.PubMedView ArticlePubMed CentralGoogle Scholar
  48. Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, et al. miR-21 mediates hematopoietic suppression in MDS by activating TGF-beta signaling. Blood. 2013;121(15):2875–81.PubMedView ArticlePubMed CentralGoogle Scholar
  49. Kim RY, Horvat JC, Pinkerton JW, Starkey MR, Essilfie AT, Mayall JR, et al. MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. J Allergy Clin Immunol. 2017;139(2):519–32.PubMedView ArticlePubMed CentralGoogle Scholar
  50. Caviglia JM, Yan J, Jang MK, Gwak GY, Affo S, Yu L, et al. MicroRNA-21 and Dicer are Dispensable for Hepatic Stellate Cell Activation and the Development of Liver Fibrosis. Hepatology (Baltimore, Md). 2018;67:2414–29.View ArticleGoogle Scholar
  51. Shi J, Bei Y, Kong X, Liu X, Lei Z, Xu T, et al. miR-17-3p contributes to exercise-induced cardiac growth and protects against myocardial ischemia-reperfusion injury. Theranostics. 2017;7(3):664–76.PubMedView ArticlePubMed CentralGoogle Scholar
  52. Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):53.PubMedView ArticlePubMed CentralGoogle Scholar
  53. Liu W, Zhang B, Chen G, Wu W, Zhou L, Shi Y, et al. Targeting miR-21 with Sophocarpine inhibits tumor progression and reverses epithelial-mesenchymal transition in head and neck Cancer. Mol Ther. 2017;25(9):2129–39.PubMedView ArticlePubMed CentralGoogle Scholar
  54. Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, et al. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther. 2014;13(12):3086–97.PubMedView ArticlePubMed CentralGoogle Scholar
  55. Egawa H, Jingushi K, Hirono T, Ueda Y, Kitae K, Nakata W, et al. The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep. 2016;6:20574.PubMedView ArticlePubMed CentralGoogle Scholar
  56. Wei H, Cui R, Bahr J, Zanesi N, Luo Z, Meng W, et al. miR-130a deregulates PTEN and stimulates tumor growth. Cancer Res. 2017;77(22):6168–78.PubMedView ArticlePubMed CentralGoogle Scholar
  57. Song CL, Liu B, Shi YF, Liu N, Yan YY, Zhang JC, et al. MicroRNA-130a alleviates human coronary artery endothelial cell injury and inflammatory responses by targeting PTEN via activating PI3K/Akt/eNOS signaling pathway. Oncotarget. 2016;7(44):71922–36.PubMedView ArticlePubMed CentralGoogle Scholar
  58. Zhang D, Yang S, Toledo EM, Gyllborg D, Salto C, Carlos Villaescusa J, et al. Niche-derived laminin-511 promotes midbrain dopaminergic neuron survival and differentiation through YAP. Sci Signal. 2017;10(493):eaal4165.PubMedView ArticlePubMed CentralGoogle Scholar
  59. Ye L, Wang Y, Nie L, Qian S, Xu M. MiR-130 exerts tumor suppressive function on the tumorigenesis of human non-small cell lung cancer by targeting PTEN. Am J Transl Res. 2017;9(4):1856–65.PubMedPubMed CentralGoogle Scholar
  60. Tian F, Han Y, Yan X, Zhong D, Yang G, Lei J, et al. Upregulation of microrna-451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis. Thoracic Cancer. 2016;7(2):226–31.PubMedView ArticlePubMed CentralGoogle Scholar
  61. Wu RL, Ali S, Bandyopadhyay S, Alosh B, Hayek K, Daaboul MF, et al. Comparative analysis of differentially expressed miRNAs and their downstream mRNAs in ovarian Cancer and its associated endometriosis. J Cancer Sci Ther. 2015;7(7):258–65.PubMedPubMed CentralGoogle Scholar
  62. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16(6):498–509.PubMedView ArticlePubMed CentralGoogle Scholar
  63. Chen J, Zhuang Y, Zhang ZF, Wang S, Jin P, He C, et al. Glycine confers neuroprotection through microRNA-301a/PTEN signaling. Mol Brain. 2016;9(1):59.PubMedView ArticlePubMed CentralGoogle Scholar
  64. Dou L, Wang S, Sui X, Meng X, Shen T, Huang X, et al. MiR-301a mediates the effect of IL-6 on the AKT/GSK pathway and hepatic glycogenesis by regulating PTEN expression. Cellular Physiol Biochem. 2015;35(4):1413–24.View ArticleGoogle Scholar
  65. Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y, et al. Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/beta-catenin signaling. Gene. 2014;535(2):191–7.PubMedView ArticlePubMed CentralGoogle Scholar
  66. Kawano M, Tanaka K, Itonaga I, Iwasaki T, Tsumura H. MicroRNA-301a promotes cell proliferation via PTEN targeting in Ewing's sarcoma cells. Int J Oncol. 2016;48(4):1531–40.PubMedView ArticlePubMed CentralGoogle Scholar
  67. Cui L, Li Y, Lv X, Li J, Wang X, Lei Z, et al. Expression of MicroRNA-301a and its functional roles in malignant melanoma. Cellular Physiol Biochem. 2016;40(1–2):230–44.View ArticleGoogle Scholar
  68. Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014;24(10):1164–80.PubMedView ArticlePubMed CentralGoogle Scholar
  69. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425–33.PubMedView ArticlePubMed CentralGoogle Scholar
  70. Jindra PT, Bagley J, Godwin JG, Iacomini J. Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. Journal of immunology (Baltimore, Md : 1950). 2010;185(2):990–7.View ArticleGoogle Scholar
  71. Lv G, Shao S, Dong H, Bian X, Yang X, Dong S. MicroRNA-214 protects cardiac myocytes against H2O2-induced injury. J Cell Biochem. 2014;115(1):93–101.PubMedView ArticlePubMed CentralGoogle Scholar
  72. Wang Y, Xu J, Gao G, Li J, Huang H, Jin H, et al. Tumor-suppressor NFkappaB2 p100 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494. Oncogene. 2016;35(31):4080–90.PubMedView ArticlePubMed CentralGoogle Scholar
  73. Wang X, Zhang X, Ren XP, Chen J, Liu H, Yang J, et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation. 2010;122(13):1308–18.PubMedView ArticlePubMed CentralGoogle Scholar
  74. Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, et al. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017;108:620–31.PubMedView ArticlePubMed CentralGoogle Scholar
  75. Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou H, et al. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep. 2017;7:41942.PubMedView ArticlePubMed CentralGoogle Scholar
  76. Zhang D, Zhou P, Wang W, Wang X, Li J, Sun X, et al. MicroRNA-616 promotes the migration, invasion and epithelial-mesenchymal transition of HCC by targeting PTEN. Oncol Rep. 2016;35(1):366–74.PubMedView ArticlePubMed CentralGoogle Scholar
  77. Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, et al. MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Invest J Tech Methods Pathol. 2015;95(9):1056–70.View ArticleGoogle Scholar
  78. Ke TW, Wei PL, Yeh KT, Chen WT, Cheng YW. MiR-92a promotes cell metastasis of colorectal Cancer through PTEN-mediated PI3K/AKT pathway. Ann Surg Oncol. 2015;22(8):2649–55.PubMedView ArticlePubMed CentralGoogle Scholar
  79. Yu T, Liu L, Li J, Yan M, Lin H, Liu Y, et al. MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget. 2015;6(30):30239–50.PubMedView ArticlePubMed CentralGoogle Scholar
  80. Guo G, Kang Q, Zhu X, Chen Q, Wang X, Chen Y, et al. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. Oncogene. 2015;34(14):1768–79.PubMedView ArticlePubMed CentralGoogle Scholar
  81. Tang J, Li L, Huang W, Sui C, Yang Y, Lin X, et al. MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial-mesenchymal transition. Cancer Lett. 2015;364(1):33–43.PubMedView ArticlePubMed CentralGoogle Scholar
  82. Zeitels LR, Acharya A, Shi G, Chivukula D, Chivukula RR, Anandam JL, et al. Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis. Genes Dev. 2014;28(23):2585–90.PubMedView ArticlePubMed CentralGoogle Scholar
  83. Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet. 2011;43(7):673–8.PubMedView ArticlePubMed CentralGoogle Scholar
  84. Wang LS, Li L, Li L, Chu S, Shiang KD, Li M, et al. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood. 2015;125(8):1302–13.PubMedView ArticlePubMed CentralGoogle Scholar
  85. Longacre M, Snyder NA, Housman G, Leary M, Lapinska K, Heerboth S, et al. A comparative analysis of genetic and epigenetic events of breast and ovarian Cancer related to tumorigenesis. Int J Mol Sci. 2016;17(5):E759.PubMedView ArticlePubMed CentralGoogle Scholar
  86. Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, et al. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016;7(26):38974–87.PubMedView ArticlePubMed CentralGoogle Scholar
  87. Yang YL, Wang FS, Li SC, Tiao MM, Huang YH. MicroRNA-29a alleviates bile duct ligation exacerbation of hepatic fibrosis in mice through epigenetic control of methyltransferases. Int J Mol Sci. 2017;18(1):E192.PubMedView ArticlePubMed CentralGoogle Scholar
  88. Zheng J, Wu C, Lin Z, Guo Y, Shi L, Dong P, et al. Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation--a novel mechanism suppressing liver fibrosis. FEBS J. 2014;281(1):88–103.PubMedView ArticlePubMed CentralGoogle Scholar
  89. Wang L, Yao J, Sun H, He K, Tong D, Song T, et al. MicroRNA-101 suppresses progression of lung cancer through the PTEN/AKT signaling pathway by targeting DNA methyltransferase 3A. Oncol Lett. 2017;13(1):329–38.View ArticlePubMedGoogle Scholar
  90. Yan F, Shen N, Pang J, Xie D, Deng B, Molina JR, et al. Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation. Cell Death Dis. 2014;5:e1413.PubMedView ArticlePubMed CentralGoogle Scholar
  91. Qadir XV, Han C, Lu D, Zhang J, Wu T. miR-185 inhibits hepatocellular carcinoma growth by targeting the DNMT1/PTEN/Akt pathway. Am J Pathol. 2014;184(8):2355–64.PubMedView ArticlePubMed CentralGoogle Scholar
  92. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147(2):358–69.PubMedView ArticlePubMed CentralGoogle Scholar
  93. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011;147(2):382–95.PubMedView ArticlePubMed CentralGoogle Scholar
  94. Shen L, Wang Q, Liu R, Chen Z, Zhang X, Zhou P, et al. LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA. Nucleic Acids Res. 2018;46:717–29.PubMedView ArticlePubMed CentralGoogle Scholar
  95. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011;147(2):344–57.PubMedView ArticlePubMed CentralGoogle Scholar
  96. Gao L, Ren W, Zhang L, Li S, Kong X, Zhang H, et al. PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma. Mol Carcinog. 2017;56(4):1322–34.PubMedView ArticlePubMed CentralGoogle Scholar
  97. Chen CL, Tseng YW, Wu JC, Chen GY, Lin KC, Hwang SM, et al. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation. Biomaterials. 2015;44:71–81.PubMedView ArticlePubMed CentralGoogle Scholar
  98. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465(7301):1033–8.PubMedView ArticlePubMed CentralGoogle Scholar
  99. Zhang R, Guo Y, Ma Z, Ma G, Xue Q, Li F, et al. Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget. 2017;8(16):26079–89.PubMedPubMed CentralGoogle Scholar
  100. Phelps M, Coss C, Wang H, Cook M. Registered report: coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. elife. 2016;5:e12470.PubMedView ArticlePubMed CentralGoogle Scholar
  101. Khan I, Kerwin J, Owen K, Griner E. Registered report: a coding-independent function of gene and pseudogene mRNAs regulates tumour biology. elife. 2015;4:e13015.PubMedView ArticlePubMed CentralGoogle Scholar
  102. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6.PubMedView ArticlePubMed CentralGoogle Scholar
  103. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6(11):846–56.PubMedView ArticlePubMed CentralGoogle Scholar
  104. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129(7):1311–23.PubMedView ArticlePubMed CentralGoogle Scholar
  105. Lai Y, He S, Ma L, Lin H, Ren B, Ma J, et al. HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy. Mol Cell Biochem. 2017;432(1–2):179–87.PubMedView ArticlePubMed CentralGoogle Scholar
  106. Sui J, Yang X, Qi W, Guo K, Gao Z, Wang L, et al. Long non-coding RNA Linc-USP16 functions as a tumour suppressor in hepatocellular carcinoma by regulating PTEN expression. Cell Physiol Biochem. 2017;44(3):1188–98.PubMedView ArticlePubMed CentralGoogle Scholar
  107. Ba Z, Gu L, Hao S, Wang X, Cheng Z, Nie G. Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR-181a. Cell Prolif. 2018;51(1):e12409.View ArticleGoogle Scholar
  108. Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo Y, et al. LncRNA CASC2 interacts with miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway. J Cell Biochem. 2017;118(7):1889–99.PubMedView ArticlePubMed CentralGoogle Scholar
  109. Feng Y, Zou W, Hu C, Li G, Zhou S, He Y, et al. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys. 2017;623–624:20–30.PubMedView ArticlePubMed CentralGoogle Scholar
  110. Yang NQ, Luo XJ, Zhang J, Wang GM, Guo JM. Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway. Am J Transl Res. 2016;8(2):1091–9.PubMedPubMed CentralGoogle Scholar
  111. Liu C, Liu Z, Li X, Tang X, He J, Lu S. MicroRNA-1297 contributes to tumor growth of human breast cancer by targeting PTEN/PI3K/AKT signaling. Oncol Rep. 2017;38(4):2435–43.PubMedView ArticlePubMed CentralGoogle Scholar
  112. Qin N, Tong GF, Sun LW, Xu XL. Long noncoding RNA MEG3 suppresses glioma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of miR-19a. Oncol Res. 2017;25(9):1471–8.PubMedView ArticlePubMed CentralGoogle Scholar
  113. Wu Z, He Y, Li D, Fang X, Shang T, Zhang H, et al. Long noncoding RNA MEG3 suppressed endothelial cell proliferation and migration through regulating miR-21. Am J Transl Res. 2017;9(7):3326–35.PubMedPubMed CentralGoogle Scholar
  114. Li W, Zhai L, Wang H, Liu C, Zhang J, Chen W, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget. 2016;7(19):27778–86.PubMedPubMed CentralGoogle Scholar
  115. Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, et al. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour Biol. 2016;37(2):2691–702.PubMedView ArticlePubMed CentralGoogle Scholar
  116. Cao L, Chen J, Ou B, Liu C, Zou Y, Chen Q. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Biomed Pharmacother. 2017;93:570–9.PubMedView ArticlePubMed CentralGoogle Scholar
  117. Tao H, Zhang JG, Qin RH, Dai C, Shi P, Yang JJ, et al. LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway. Toxicology. 2017;386:11–8.PubMedView ArticlePubMed CentralGoogle Scholar
  118. Guo C, Song WQ, Sun P, Jin L, Dai HY. LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J Biomed Sci. 2015;22:100.PubMedView ArticlePubMed CentralGoogle Scholar
  119. Yang W, Hong L, Xu X, Wang Q, Huang J, Jiang L. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. Tumour Biol. 2017;39(7):1010428317711315.PubMedPubMed CentralGoogle Scholar
  120. Gao ZQ, Wang JF, Chen DH, Ma XS, Wu Y, Tang Z, et al. Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell Biosci. 2017;7:66.PubMedView ArticlePubMed CentralGoogle Scholar
  121. Chang S, Chen B, Wang X, Wu K, Sun Y. Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression. BMC Cancer. 2017;17(1):248.PubMedView ArticlePubMed CentralGoogle Scholar
  122. Gu S, Xie R, Liu X, Shou J, Gu W, Che X. Long coding RNA XIST contributes to neuronal apoptosis through the downregulation of AKT phosphorylation and is negatively regulated by miR-494 in rat spinal cord injury. Int J Mol Sci. 2017;18(4):E732.PubMedView ArticlePubMed CentralGoogle Scholar
  123. Yang C, Wang G, Yang J, Wang L. Long noncoding RNA NBAT1 negatively modulates growth and metastasis of osteosarcoma cells through suppression of miR-21. Am J Cancer Res. 2017;7(10):2009–19.PubMedPubMed CentralGoogle Scholar
  124. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013;8(6):e66855.PubMedView ArticlePubMed CentralGoogle Scholar
  125. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.PubMedView ArticlePubMed CentralGoogle Scholar
  126. Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, et al. Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nat Commun. 2016;7:10982.PubMedView ArticlePubMed CentralGoogle Scholar
  127. Li J, An G, Zhang M, Ma Q. Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells. Biochem Biophys Res Commun. 2016;477(4):743–8.PubMedView ArticlePubMed CentralGoogle Scholar
  128. Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y, et al. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep. 2014;4:6088.PubMedView ArticlePubMed CentralGoogle Scholar
  129. Qiao Q, Li H. LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. Biochem Biophys Res Commun. 2016;478(2):507–12.PubMedView ArticlePubMed CentralGoogle Scholar
  130. Yue B, Sun B, Liu C, Zhao S, Zhang D, Yu F, et al. Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. Cancer Sci. 2015;106(10):1323–32.PubMedView ArticlePubMed CentralGoogle Scholar
  131. Xia T, Chen S, Jiang Z, Shao Y, Jiang X, Li P, et al. Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. Sci Rep. 2015;5:13445.PubMedView ArticlePubMed CentralGoogle Scholar
  132. Yu F, Lu Z, Chen B, Dong P, Zheng J. Identification of a novel lincRNA-p21-miR-181b-PTEN signaling Cascade in liver fibrosis. Mediat Inflamm. 2016;2016:9856538.View ArticleGoogle Scholar
  133. Johnsson P, Ackley A, Vidarsdottir L, Lui WO, Corcoran M, Grander D, et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol. 2013;20(4):440–6.PubMedView ArticlePubMed CentralGoogle Scholar
  134. Yu F, Chen B, Dong P, Zheng J. HOTAIR epigenetically modulates PTEN expression via MicroRNA-29b: a novel mechanism in regulation of liver fibrosis. Mol Ther. 2017;25(1):205–17.PubMedView ArticlePubMed CentralGoogle Scholar
  135. Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J, et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol. 2013;182(1):64–70.PubMedView ArticlePubMed CentralGoogle Scholar
  136. Lister N, Shevchenko G, Walshe JL, Groen J, Johnsson P, Vidarsdottir L, et al. The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene. Proc Natl Acad Sci U S A. 2017;114(37):9942–7.PubMedView ArticlePubMed CentralGoogle Scholar
  137. Wang WJ, Yang W, Ouyang ZH, Xue JB, Li XL, Zhang J, et al. MiR-21 promotes ECM degradation through inhibiting autophagy via the PTEN/akt/mTOR signaling pathway in human degenerated NP cells. Biomed Pharmacother. 2018;99:725–34.PubMedView ArticlePubMed CentralGoogle Scholar
  138. Li L, Wang Z, Hu X, Wan T, Wu H, Jiang W, et al. Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2016;479(2):343–50.PubMedView ArticlePubMed CentralGoogle Scholar
  139. Yan L, Cao R, Liu Y, Wang L, Pan B, Lv X, et al. MiR-21-5p links epithelial-mesenchymal transition phenotype with stem-like cell signatures via AKT signaling in keloid keratinocytes. Sci Rep. 2016;6:28281.PubMedView ArticlePubMed CentralGoogle Scholar
  140. Bahena-Ocampo I, Espinosa M, Ceballos-Cancino G, Lizarraga F, Campos-Arroyo D, Schwarz A, et al. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation. EMBO Rep. 2016;17(5):648–58.PubMedView ArticlePubMed CentralGoogle Scholar
  141. Yuan L, Lv Y, Li H, Gao H, Song S, Zhang Y, et al. Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol. 2015;17(9):1169–81.PubMedView ArticlePubMed CentralGoogle Scholar
  142. Peyrou M, Bourgoin L, Poher AL, Altirriba J, Maeder C, Caillon A, et al. Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice. J Hepatol. 2015;62(2):421–9.PubMedView ArticlePubMed CentralGoogle Scholar
  143. Xu L, Fan Q, Wang X, Li L, Lu X, Yue Y, et al. Ursolic acid improves podocyte injury caused by high glucose. Nephrol Dial Transplant. 2017;32(8):1285–93.PubMedView ArticlePubMed CentralGoogle Scholar
  144. Zhou X, Ren Y, Liu A, Jin R, Jiang Q, Huang Y, et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Sci Rep. 2014;4:7461.PubMedView ArticlePubMed CentralGoogle Scholar
  145. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016;7(42):68371–84.PubMedView ArticlePubMed CentralGoogle Scholar
  146. Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011;28(12):3091–100.PubMedView ArticlePubMed CentralGoogle Scholar


© The Author(s). 2018